UHN — which includes Toronto General Hospital, Toronto Western, the Princess Margaret Cancer Centre and Toronto Rehabilitation Institute — suggests the new approach increases the likelihood of finding new therapies faster.
According to Eleanor Fish, PhD, senior scientist in the Toronto General Research Institute, the research team tested Ebola drug combinations as part of their study since lower drug doses may reduce unpleasant side effects.
“Using this technology, scientists will be able to measure the inhibitory effects of their experimental drugs on the replication of Ebola virus, allowing us to compare results with confidence,” said Dr. Fish. “This approach will also decrease the possibility of the emergence of drug resistance.”
The team’s results were validated using fully infectious Ebola virus in a laboratory setting.
More articles on Ebola:
Treating Ebola patients with blood transfusions of survivors is ineffective, study shows
Rhode Island stops Ebola monitoring program
Ohio left with one Ebola treatment center after UTMC drops designation: 3 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.